Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

Launched by MEDEOR THERAPEUTICS, INC. · Nov 30, 2017

Keywords

ClinConnect Summary

Currently, patients receiving a transplanted kidney are required to take life-long immunosuppressive medications to prevent rejection of the transplanted kidney. These medications carry substantial side effects. In addition, these medicines often do not completely control damage to the kidney from the recipients' immune system, ultimately causing the kidney to fail.

Medeor Therapeutics is developing a novel cell-based therapy to reprogram the recipients' immune system to accept a transplanted kidney without the need for long term use of immunosuppression drugs.

The purpose of the current ...

Gender

ALL

Eligibility criteria

• Recipient Inclusion Criteria:
• • Planned recipient of a first kidney allograft from an HLA-matched, living related donor
• • Age ≥18 and ≤70 years
• • Single solid organ recipient (kidney only)
• • ABO matched with donor
• Recipient Exclusion Criteria:
• • Underlying kidney disease with a high risk of disease recurrence in the transplanted kidney
• • Baseline positive donor-specific anti-HLA antibody testing
• • Is taking immunosuppressive therapy
• • Evidence of prior hepatitis B (HBV) or hepatitis C (HCV)
• Donor Inclusion Criteria:
• • HLA-matched first degree (parent, child or sibling) or second-degree (child of a sibling or half sibling) relative of the prospective recipient participant
• • Age ≥18 and ≤70 years
• • Prepared to be a living related kidney donor, and capable of undergoing G-CSF mobilization and apheresis of hematopoietic cells
• Donor Exclusion Criteria:
• • History of autoimmune disorders
• • History of type 1 or type 2 diabetes mellitus
• • Tests confirmed positive for human immunodeficiency virus (HIV), HBV, HCV, T. cruzi, or syphilis
• • History of infection with Zika virus